

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**

**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

**SUPPLEMENTAL ANNOUNCEMENT  
DISCLOSEABLE TRANSACTION  
FORMATION OF THE LIMITED PARTNERSHIP**

Reference is made to the announcement of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) dated December 6, 2024 in relation to the formation of a limited partnership (the “**Announcement**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board wishes to provide the following supplemental information in relation to the formation of the Limited Partnership.

**INFORMATION ON THE PARTNERS**

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, Shanghai Zhuorei is controlled by Shenzhen Ruiersi Management Consulting Co., Ltd.\* (深圳市睿爾斯管理諮詢有限公司), which is owned as to 90% and 10% by Gao Song (高松) and Shen Lu (沈璐), both being Independent Third Parties, respectively.

**REASONS FOR AND BENEFITS OF THE FORMATION OF THE LIMITED PARTNERSHIP**

According to the Limited Partnership Agreement, there is no lock-up period on the capital contributions by the partners to the Limited Partnership. As disclosed in the Announcement, the capital contribution to be made by the Company to the Limited Partnership will be funded by internal resources of the Group, and the Group will maintain sufficient funding for its

research and development following the capital contribution. Hence, the capital contribution to be made by the Company will not have any material impact on its research and development of product pipelines.

Save as disclosed in this announcement, all other information contained in the Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People's Republic of China, December 23, 2024

*As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.*

\* *For identification purpose only.*